PBC1
MCID: BLR024
MIFTS: 38

Biliary Cirrhosis, Primary, 1 (PBC1)

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Biliary Cirrhosis, Primary, 1

MalaCards integrated aliases for Biliary Cirrhosis, Primary, 1:

Name: Biliary Cirrhosis, Primary, 1 58 13
Primary Biliary Cirrhosis 74
Pbc1 58
Pbc 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
biliary cirrhosis, primary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 58 109720
SNOMED-CT via HPO 70 1761006 263681008 31712002
UMLS 74 C0008312

Summaries for Biliary Cirrhosis, Primary, 1

OMIM : 58 Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease that usually affects middle-aged women and eventually leads to liver failure (summary by Kaplan, 1996). (109720)

MalaCards based summary : Biliary Cirrhosis, Primary, 1, also known as primary biliary cirrhosis, is related to biliary cirrhosis, primary, 2 and reynolds syndrome. The drugs Ursodeoxycholic acid and chenodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and bone, and related phenotype is biliary cirrhosis.

Related Diseases for Biliary Cirrhosis, Primary, 1

Graphical network of the top 20 diseases related to Biliary Cirrhosis, Primary, 1:



Diseases related to Biliary Cirrhosis, Primary, 1

Symptoms & Phenotypes for Biliary Cirrhosis, Primary, 1

Human phenotypes related to Biliary Cirrhosis, Primary, 1:

33
# Description HPO Frequency HPO Source Accession
1 biliary cirrhosis 33 HP:0002613

Symptoms via clinical synopsis from OMIM:

58
G I:
primary biliary cirrhosis

Lab:
impaired in vitro igg suppression

Clinical features from OMIM:

109720

Drugs & Therapeutics for Biliary Cirrhosis, Primary, 1

Drugs for Biliary Cirrhosis, Primary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
2
chenodeoxycholic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1 474-25-9 10133
3
Abatacept Approved Phase 4 332348-12-6 10237
4
Methionine Approved, Nutraceutical Phase 4,Phase 2 63-68-3 6137
5 Liver Extracts Phase 4,Phase 3,Phase 2,Not Applicable
6 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Cholagogues and Choleretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Cathartics Phase 4,Phase 3,Phase 2,Early Phase 1
11 Laxatives Phase 4,Phase 3,Phase 2,Early Phase 1
12 Immunosuppressive Agents Phase 4,Phase 3,Not Applicable
13
Fenofibrate Approved Phase 3,Phase 1,Phase 2 49562-28-9 3339
14
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
15
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
16
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
17
Molybdenum Approved Phase 3 7439-98-7 185498
18
Copper Approved, Investigational Phase 3 7440-50-8 27099
19
Atorvastatin Approved Phase 3 134523-00-5 60823
20
Budesonide Approved Phase 3,Phase 1,Not Applicable 51333-22-3 5281004 63006
21
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
22
Colchicine Approved Phase 3 64-86-8 2833 6167
23
leucovorin Approved Phase 3 58-05-9 143 6006
24
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
25
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Tauroursodeoxycholic acid Experimental, Investigational Phase 3 14605-22-2 12443252
28
Taurochenodeoxycholic acid Experimental Phase 3 516-35-8 387316
29
Tetrathiomolybdate Investigational Phase 3 16330-92-0
30 Antimetabolites Phase 3,Phase 1,Phase 2
31 Lipid Regulating Agents Phase 3,Phase 1,Phase 2
32 Hypolipidemic Agents Phase 3,Phase 1,Phase 2
33 Anti-HIV Agents Phase 2, Phase 3,Not Applicable
34 Lamivudine, zidovudine drug combination Phase 2, Phase 3
35 Anti-Retroviral Agents Phase 2, Phase 3,Not Applicable
36 Antiviral Agents Phase 2, Phase 3,Phase 3,Not Applicable
37 Reverse Transcriptase Inhibitors Phase 2, Phase 3,Not Applicable
38 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable
40 Angiogenesis Modulating Agents Phase 3
41 Nutrients Phase 3,Not Applicable
42 Chelating Agents Phase 3
43 Trace Elements Phase 3,Not Applicable
44 Micronutrients Phase 3,Not Applicable
45 Angiogenesis Inhibitors Phase 3
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
47 Anticholesteremic Agents Phase 3,Phase 1
48 Anti-Inflammatory Agents Phase 3,Phase 1,Not Applicable
49 Bronchodilator Agents Phase 3,Phase 1,Not Applicable
50 Respiratory System Agents Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
2 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Completed NCT02078882 Phase 4
3 Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
4 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
5 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
6 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
7 Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02823353 Phase 3 Fenofibrate;UDCA
8 Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Unknown status NCT02916290 Phase 3 Fuzhenghuayu;UDCA
9 Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02823366 Phase 3 Fenofibrate;UDCA
10 Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid Unknown status NCT02916641 Phase 3 Fuzhenghuayu;UDCA
11 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
12 Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy Unknown status NCT02721862 Phase 3 Ursodeoxycholic Acid;Placebo
13 Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Recruiting NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
14 Study of Combivir for Patients With Primary Biliary Cirrhosis Completed NCT00490620 Phase 2, Phase 3 Combination antiviral therapy;Placebo
15 Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis Completed NCT01857284 Phase 3 Tauroursodeoxycholic Acid Capsules;Ursodeoxycholic Acid Capsules
16 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Completed NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
17 Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis Completed NCT00805805 Phase 3 Tetrathiomolybdate
18 Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 2, Phase 3 Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
19 Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis Completed NCT00844402 Phase 3 Atorvastatin
20 Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC) Terminated NCT00746486 Phase 3 budesonide;budesonide placebo
21 ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Recruiting NCT03602560 Phase 3 seladelpar 5-10 mg;seladelpar 10 mg;Placebo
22 Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed NCT00004748 Phase 3 colchicine;methotrexate;ursodiol
23 Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis Completed NCT01654731 Phase 3 Bezafibrate;placebo
24 Ursodiol-Methotrexate for Primary Biliary Cirrhosis Completed NCT00006168 Phase 3 Methotrexate
25 Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis Completed NCT00004784 Phase 3 methotrexate;ursodiol
26 Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC Completed NCT01829698 Phase 3 tauroursodeoxycholic;ursodeoxycholic acid
27 Metformin in Intrahepatic Cholestasis of Pregnancy Not yet recruiting NCT03056274 Phase 2, Phase 3 Metformin;Ursodeoxycholic Acid
28 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
29 Pilot Study of FFP104 Dose Escalation in PBC Subjects Unknown status NCT02193360 Phase 1, Phase 2 FFP104
30 Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA Unknown status NCT02965911 Phase 1, Phase 2 Fenofibrate;UDCA
31 Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
32 Moexipril for Primary Biliary Cirrhosis Completed NCT00588302 Phase 2 Moexipril
33 Initial Study of Rituximab to Treat Primary Biliary Cirrhosis Completed NCT00364819 Phase 1, Phase 2 rituximab
34 Use of Fenofibrate for Primary Biliary Cirrhosis Completed NCT00575042 Phase 2 Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
35 A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid Completed NCT01389973 Phase 2 ustekinumab 90 mg;ustekinumab 45 mg;ustekinumab 180 mg;Placebo
36 Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis Completed NCT02135536 Phase 2
37 An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis Withdrawn NCT02321306 Phase 2 LUM001
38 Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis Completed NCT02026401 Phase 2
39 Pentoxifylline for Primary Biliary Cirrhosis Completed NCT01249092 Phase 2 Pentoxifylline
40 B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis Completed NCT02376335 Phase 2
41 Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) Terminated NCT02609048 Phase 2 Placebo Comparator;Experimental: Seladelpar / MBX-8025 50 mg;Experimental: Seladelpar / MBX-8025 200 mg
42 Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis Withdrawn NCT01141296 Phase 2 fenofibrate;placebo
43 A Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS) Recruiting NCT03112681 Phase 2 Saroglitazar magnesium 2 mg;Saroglitazar magnesium 4 mg;Placebo Oral Tablet
44 Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Active, not recruiting NCT02955602 Phase 2 MBX-8025 2 mg Capsule;MBX-8025 5 mg Capsule;MBX-8025 10 mg Capsule
45 Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Completed NCT01904058 Phase 2 LUM001;Placebo;Ursodeoxycholic Acid
46 Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis Completed NCT01865812 Phase 2 obeticholic acid (OCA)
47 Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Active, not recruiting NCT03226067 Phase 2 GKT137831;Placebo oral capsule
48 Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody Terminated NCT01430429 Phase 2 NI-0801
49 Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid Terminated NCT03092765 Phase 2 E6011;Placebo
50 A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA Recruiting NCT03742973 Phase 2 Baricitinib;Placebo

Search NIH Clinical Center for Biliary Cirrhosis, Primary, 1

Genetic Tests for Biliary Cirrhosis, Primary, 1

Anatomical Context for Biliary Cirrhosis, Primary, 1

MalaCards organs/tissues related to Biliary Cirrhosis, Primary, 1:

42
Liver, T Cells, Bone, B Cells, Testes, Lung, Thyroid

Publications for Biliary Cirrhosis, Primary, 1

Articles related to Biliary Cirrhosis, Primary, 1:

(show top 50) (show all 3214)
# Title Authors Year
1
Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. ( 30575642 )
2019
2
Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report. ( 29465536 )
2018
3
Lp8 is potentially associated with partial lecithin:cholesterol acyltransferase deficiency in a patient with primary biliary cirrhosis. ( 30055975 )
2018
4
Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sjögren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review. ( 29745886 )
2018
5
Palmoplantar keratoderma as a presenting sign of primary biliary cirrhosis. ( 29270458 )
2018
6
Lower Plasma Levels of IL-35 in Patients with Primary Biliary Cirrhosis. ( 29445068 )
2018
7
IgG4-related retroperitoneal fibrosis overlapping with primary biliary cirrhosis and primary Sjögren's syndrome: A case report. ( 29953016 )
2018
8
IgM-Positive Tubulointerstitial Nephritis Associated With Asymptomatic Primary Biliary Cirrhosis. ( 29988993 )
2018
9
Increased risk of osteoporosis in patients with primary biliary cirrhosis. ( 29543880 )
2018
10
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab. ( 30246126 )
2018
11
Interstitial granulomatous dermatitis associated with primary biliary cirrhosis. ( 28225148 )
2018
12
Primary biliary cirrhosis with refractory hypokalemia: A case report. ( 30508897 )
2018
13
Xanthoma Striatum Palmare in a Patient of Primary Biliary Cirrhosis with Autoimmune Hepatitis. ( 28566919 )
2017
14
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. ( 28823616 )
2017
15
Autoimmune Hepatitis - Primary Biliary Cirrhosis Overlap Syndrome. ( 28892963 )
2017
16
Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? ( 27475095 )
2017
17
Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. ( 27538899 )
2017
18
Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation. ( 27754570 )
2017
19
Red blood cell distribution width and mean platelet volume are potential prognostic indices for patients with primary biliary cirrhosis. ( 27754960 )
2017
20
A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea. ( 28197333 )
2017
21
Spontaneous Splenic Infarcts in a Cirrhotic Patient with Primary Biliary Cirrhosis. ( 28203139 )
2017
22
Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea. ( 28229620 )
2017
23
Prediction of oesophageal varices in patients with primary biliary cirrhosis by non-invasive markers. ( 28261290 )
2017
24
Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases. ( 28352320 )
2017
25
Concurrent Occurrence of Primary Biliary Cirrhosis and Rheumatoid Arthritis. ( 29057174 )
2017
26
Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis. ( 29113177 )
2017
27
Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. ( 27864100 )
2017
28
Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. ( 27189879 )
2017
29
A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. ( 27148676 )
2017
30
Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. ( 26893441 )
2017
31
The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. ( 26388238 )
2017
32
An Atypical Syndrome in an Elderly Patient With Systemic Lupus Erythematosus, Sjögren Syndrome, and Primary Biliary Cirrhosis. ( 30375531 )
2017
33
Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. ( 28570655 )
2017
34
[Single nucleotide polymorphism of STAT4 rs7574865 is associated with the susceptibility of primary biliary cirrhosis in Han population of partial regions of Jiangsu province]. ( 28395724 )
2017
35
A Case of Frontal Fibrosing Alopecia in a Patient with Primary Biliary Cirrhosis and Polymyalgia Rheumatica. ( 27843932 )
2016
36
Changing nomenclature for PBC from "primary biliary cirrhosis" to "primary biliary cholangitis". ( 27101399 )
2016
37
Changing Nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis". ( 27230619 )
2016
38
Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators. ( 27298571 )
2016
39
Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list-a case study. ( 27429732 )
2016
40
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. ( 27431238 )
2016
41
Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials. ( 27458850 )
2016
42
Identification of microRNA profiles associated with refractory primary biliary cirrhosis. ( 27511723 )
2016
43
Liver damage in primary biliary cirrhosis and accompanied by primary Sjögren's syndrome: a retrospective pilot study. ( 27536204 )
2016
44
A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis. ( 27537780 )
2016
45
Obeticholic acid for the treatment of primary biliary cirrhosis. ( 27589928 )
2016
46
Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. ( 27672278 )
2016
47
Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis. ( 27707675 )
2016
48
Pulmonary Manifestations among Patients with Primary Biliary Cirrhosis. ( 27777894 )
2016
49
Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. ( 28070198 )
2016
50
A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. ( 28839853 )
2016

Variations for Biliary Cirrhosis, Primary, 1

Expression for Biliary Cirrhosis, Primary, 1

Search GEO for disease gene expression data for Biliary Cirrhosis, Primary, 1.

Pathways for Biliary Cirrhosis, Primary, 1

GO Terms for Biliary Cirrhosis, Primary, 1

Sources for Biliary Cirrhosis, Primary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....